Fibrinolysis and atherosclerosis.
作者信息
Collen D, Juhan-Vague I
机构信息
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
出版信息
Semin Thromb Hemost. 1988 Apr;14(2):180-3. doi: 10.1055/s-2007-1002773.
PMID:3144739
Abstract
摘要
相似文献
1
Fibrinolysis and atherosclerosis.纤维蛋白溶解与动脉粥样硬化。
Semin Thromb Hemost. 1988 Apr;14(2):180-3. doi: 10.1055/s-2007-1002773.
2
[Lipoprotein-mediated functional changes in the fibrinolytic system in the genesis of atherosclerosis].[脂蛋白介导的纤溶系统功能变化在动脉粥样硬化发生中的作用]
Sangre (Barc). 1991 Feb;36(1):25-8.
3
Regulation of fibrinolysis in the development of atherothrombosis: role of adipose tissue.
Thromb Haemost. 1999 Aug;82(2):832-6.
4
Fibrinolytic system in atherosclerosis.
Semin Thromb Hemost. 1986 Apr;12(2):91-101. doi: 10.1055/s-2007-1003541.
5
Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.纤维蛋白特异性在治疗性溶栓中的重要性以及使用组织型纤溶酶原激活剂和尿激酶原的序贯与协同组合的原理。
Semin Thromb Hemost. 1989 Apr;15(2):123-8. doi: 10.1055/s-2007-1002694.
6
Fibrinolytic activity in peripheral atherosclerosis in the elderly.老年人外周动脉粥样硬化中的纤溶活性。
Thromb Haemost. 1999 Feb;81(2):275-80.
7
8
[Fibrinolytic system and hyperinsulinism].[纤溶系统与高胰岛素血症]
Journ Annu Diabetol Hotel Dieu. 1990:181-91.
9
Stimulated tissue plasminogen activator release as a marker of endothelial function in humans.刺激组织纤溶酶原激活物释放作为人类内皮功能的标志物。
Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2470-9. doi: 10.1161/01.ATV.0000189309.05924.88. Epub 2005 Oct 6.
10
Clinical application of fibrinolysis laboratory tests: a review.纤维蛋白溶解实验室检测的临床应用：综述
Ann Ital Med Int. 1998 Apr-Jun;13(2):81-7.
引用本文的文献
1
Impact of lysophosphatidylcholine on the plasminogen activator system in cultured vascular smooth muscle cells.溶血磷脂酰胆碱对培养血管平滑肌细胞纤溶酶原激活系统的影响。
J Korean Med Sci. 2012 Jul;27(7):803-10. doi: 10.3346/jkms.2012.27.7.803. Epub 2012 Jun 29.
2
High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction.冠心病患者中纤溶酶原激活物抑制物活性较高，与甘油三酯和高密度脂蛋白胆固醇值相关，心肌梗死幸存者之间无差异。
Ann Hematol. 1993 Nov;67(5):237-44. doi: 10.1007/BF01715054.
3
Pathogenesis of atherosclerosis: state of the art.
Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:993-1004. doi: 10.1007/BF02018308.
4
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries.人动脉粥样硬化中1型纤溶酶原激活物抑制剂基因表达增加。
Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):6998-7002. doi: 10.1073/pnas.89.15.6998.
Zotero 插件